Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Namenda/Memantine Clear all
Terminated Phase 4 Interventional Results available

Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury

NCT00462228
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder

NCT00411398
View directory record Official record
Conditions
General Anxiety Disorder, Social Anxiety Disorder
Interventions
Namenda/Memantine
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 7, 2026, 2:33 PM EDT
Not listed Phase 4 Interventional

Memantine for Post-Operative Pain Control

NCT01041313
View directory record Official record
Conditions
Pain, Post-operative
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 3 Interventional

An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease

NCT00097916
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
9
States / cities
San Francisco, California • Westminster, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Not applicable Interventional Results available

An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder

NCT01038128
View directory record Official record
Conditions
Bulimia Nervosa, Body Dysmorphic Disorder
Interventions
Memantine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Not applicable Interventional Results available

Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

NCT00186498
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
memantine, Placebo Oral Capsule
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 4 Interventional

An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder

NCT00330655
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
memantine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
16 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2007 · Synced Oct 7, 2026, 2:33 PM EDT
Completed No phase listed Observational

Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment

NCT01364818
View directory record Official record
Conditions
Autism Spectrum Disorders, Psychosis, Fragile X Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 4 Interventional Results available

Memantine Augmentation of Antidepressants

NCT00344682
View directory record Official record
Conditions
Depressive Disorder
Interventions
memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 4 Interventional Results available

Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS

NCT00586573
View directory record Official record
Conditions
ADHD
Interventions
memantine hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil

NCT00829816
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Los Alamitos, California • National City, California • Delray Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 7, 2026, 2:33 PM EDT
Terminated Phase 4 Interventional

Namenda to Prevent Post-Operative Delirium

NCT00303433
View directory record Official record
Conditions
Delirium, Post-Operative States
Interventions
Namenda
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 4 Interventional Results available

Memantine for Spasticity in MS Patients

NCT00638027
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
placebo, memantine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 4 Interventional Results available

Memantine and Cognitive Dysfunction in Bipolar Disorder

NCT00586066
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Memantine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Not applicable Interventional Results available

Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus

NCT00928954
View directory record Official record
Conditions
Nystagmus
Interventions
gabapentin, memantine
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment

NCT01876823
View directory record Official record
Conditions
Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
Interventions
es-citalopram, Memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Memantine in Treating Cocaine-Dependent Individuals - 2

NCT00134901
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Memantine, placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 2 Interventional

Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients

NCT00097942
View directory record Official record
Conditions
Schizophrenia
Interventions
memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
National City, California • San Diego, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 7, 2026, 2:33 PM EDT
Terminated Phase 3 Interventional

Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions

NCT03553875
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder, Nonverbal Learning Disability
Interventions
Memantine Hydrochloride, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 4 Interventional

Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)

NCT00334906
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder

NCT01972074
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Memantine, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 7, 2026, 2:33 PM EDT
Recruiting Phase 2 Interventional

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique

NCT05045950
View directory record Official record
Conditions
Brain Metastases
Interventions
Memantine -Twice Daily or Extended Release, WBRT utilizing the PRDR technique
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Not applicable Interventional Results available

Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?

NCT01054599
View directory record Official record
Conditions
Epilepsy
Interventions
Memantine, Sugar Pill
Drug · Other
Lead sponsor
American Academy of Neurology
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 7, 2026, 2:33 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)

NCT00000867
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Memantine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 7, 2026, 2:33 PM EDT